What Are The Differences Between Gabapentin And Lyrica?

Gabapentin was discovered by a group of Japanese scientists as early as 40 years ago. It was introduced in the United States by the pharmaceutical company Parke-Davis back in 2004 under the trade name Neurontin. Parke-Davis’s parent company Pfizer considers Neurontin as one of its best-selling drugs.

Lyrica is another popular drug marketed by the pharmaceutical giant Pfizer. The United States’ Food and Drug Administration approved its use the same year Neurontin came to the US. Unlike Gabapentin, the Drug Enforcement Agency regulates Lyrica as a Schedule V drug. (1)

Uses Of Lyrica And Gabapentin

Gabapentin is an anticonvulsant, an anti-epileptic medication. It can treat epilepsy as well as nerve pain from shingles by altering body chemicals, which in turn affect nerves in the body.

Lyrica, also known as pregabalin, is chemically related to Gabapentin. Like the latter, it is also an anti-epileptic medication. However, studies have proven that Lyrica can cure more diseases. Aside from nerve pain caused by shingles, it can also treat those caused by diabetes, spinal cord injury, and fibromyalgia.

Evidently, Lyrica proves to be the more superior drug, being a cure for a wider range of diseases. However, before deciding which of the two you should take, there are more things that you should consider.

What Are The Side Effects Common Between Lyrica And Gabapentin?

  •       Chest pain and trouble breathing
  •       Mood behavior and depression
  •       Muscle Pain
  •       Vision Problems
  •       Problems with memory and concentration
  •       Tremors
  •       Dizziness
  •       Drowsiness

Side Effects Of Lyrica (2)

  •       Easy bruising or bleeding
  •       Swelling in your hands or feet
  •       Rapid weight gain
  •       Loss of balance or coordination
  •       Breast swelling
  •       Dry mouth
  •       Constipation

Side Effects Of Gabapentin (3)

  •       Increased seizures
  •       Severe weakness or tiredness
  •       Upper stomach pain
  •       Kidney problems: little or painful urination and swelling of feet or ankles
  •       Severe skin reaction: fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain followed by a red or purple skin rash that spreads and causes blistering and peeling
  •       Headache

Which Is Cheaper Between Lyrica And Gabapentin?

Gabapentin is the more popular option between the two. Looking only at the per unit value of both drugs, it comes cheaper with the lowest price available only at $13.38 for 90 capsules or $0.1497 each. Unlike Lyrica, this has a variety of generic options. (4)

On the other hand, Lyrica commands a higher price from the market. To purchase a 75mg (60 capsules) bottle, you will have to make your pocket $431.10 lighter. Hence, one tablet costs about $7.185 each, which is 4,800 percent higher compared to Gabapentin. However, doctors speculate that a generic version of the drug will be available by 2019 hopefully lowering its price. (5)

Effectiveness Of Lyrica And Gabapentin

Clinical trials have proven Lyrica to be more effective in treating neuropathic pain compared to Gabapentin. In fact, a lower dosage of Lyrica can cure the same sickness owing to its high absorption rate. It’s plasma concentrations increase linearly with the dose.

The same goes for partial epilepsy. In comparison, 150mg to 600mg of Lyrica was shown to be more effective than 900mg to 2400mg of Gabapentin. (6) (7)


With everything said, Lyrica remains to be the more viable choice for both neuropathic pain and epilepsy. It may be the more expensive option. However, it requires a lower dosage to acquire the same results.


Lyrica. (n.d.) Retrieved August 7, 2017, from https://www.drugs.com/lyrica.html

Gabapentin. (n.d.) Retrieved August 7, 2017, from https://www.drugs.com/gabapentin.html

How does pregabalin compare to gabapentin in the treatment of neuropathic pain? by McAuley. (n.d.). Retrieved August 7, 2017, fromhttp://www.globalrph.com/pregabalin.htm

Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships by Delahoy, Thompson, and Marschner. (2010). Retrieved August 7, 2017, from https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-10-104